Proteomic analysis of liver mitochondria from rats with nonalcoholic steatohepatitis

World Journal of Gastroenterology

Volumn 20, Issue 16, 2014, Pages 4778-4786

  Li, Lin ^a   Lu, De Zhao ^b   Li, You Ming ^a   Zhang, Xue Qun ^a   Zhou, Xin Xin ^a   Jin, Xi ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Hadha; Nonalcoholic steatohepatitis; Proteomics; Rat model

Indexed keywords

AGMATINASE; ALANINE AMINOTRANSFERASE; ALDEHYDE DEHYDROGENASE; ASPARTATE AMINOTRANSFERASE; CARBAMOYL PHOSPHATE SYNTHASE; CHOLESTEROL; ESTRADIOL 17BETA DEHYDROGENASE 8; GLUCURONOSYLTRANSFERASE 2B31; HADHA PROTEIN; PEPTIDES AND PROTEINS; PROHIBITIN; PROTEIN NDUFB10; THYROXINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; MITOCHONDRIAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CENTRIFUGATION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; LIVER MITOCHONDRION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; PROTEOMICS; RAT; TWO DIMENSIONAL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING; ANIMAL; BIOLOGY; DISEASE MODEL; GENE ONTOLOGY; LIPID DIET; LIVER; MASS SPECTROMETRY; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; BLOTTING, WESTERN; COMPUTATIONAL BIOLOGY; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE ONTOLOGY; LIVER; MITOCHONDRIA, LIVER; MITOCHONDRIAL PROTEINS; NON-ALCOHOLIC FATTY LIVER DISEASE; PROTEOMICS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84899658593     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i16.4778     Document Type: Article

References (33)

1. Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2010; 26: 202-208 [PMID: 20168226 DOI: 10.1097/MOG.0b013e328337b0c4]
2. Kopec KL, Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract 2011; 26: 565-576 [PMID: 21947639 DOI: 10.1177/0884533611419668]
3. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873 [PMID: 17006923 DOI: 10.1002/hep.21327]
4. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140 [PMID: 12105842 DOI: 10.1053/gast.2002.34168]
5. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845 [PMID: 9547102 DOI: 10.1016/S0016-5085(98)70599-2]
6. Bohinc BN, Diehl AM. Mechanisms of disease progression in NASH: new paradigms. Clin Liver Dis 2012; 16: 549-565 [PMID: 22824480 DOI: 10.1016/j.cld.2012.05.002]
7. Grattagliano I, de Bari O, Bernardo TC, Oliveira PJ, Wang DQ, Portincasa P. Role of mitochondria in nonalcoholic fatty liver disease--from origin to propagation. Clin Biochem 2012; 45: 610-618 [PMID: 22484459 DOI: 10.1016/j.clinbiochem.201 2.03.024]
8. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005; 42: 928-940 [PMID: 15885365 DOI: 10.1016/ j.jhep.2005.03.004]
9. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1-28 [PMID: 16406828 DOI: 10.1016/j.mito.2005.10.004]
10. Hanash S. Disease proteomics. Nature 2003; 422: 226-232 [PMID: 12634796 DOI: 10.1038/nature01514]
11. Zhang X, Yang J, Guo Y, Ye H, Yu C, Xu C, Xu L, Wu S, Sun W, Wei H, Gao X, Zhu Y, Qian X, Jiang Y, Li Y, He F. Functional proteomic analysis of nonalcoholic fatty liver disease in rat models: enoyl-coenzyme a hydratase down-regulation exacerbates hepatic steatosis. Hepatology 2010; 51: 1190-1199 [PMID: 20162621 DOI: 10.1002/hep.23486]
12. Xu C, Zhang X, Yu C, Lu G, Chen S, Xu L, Ding W, Shi Q, Li Y. Proteomic analysis of hepatic ischemia/reperfusion injury and ischemic preconditioning in mice revealed the protective role of ATP5β. Proteomics 2009; 9: 409-419 [PMID: 19142948 DOI: 10.1002/pmic.200800393]
13. Yu C, Xu C, Xu L, Yu J, Miao M, Li Y. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol 2012; 56: 241-247 [PMID: 21756851 DOI: 10.1016/j.jhep.2011.05.027]
14. Chen YP, Jin X, Xiang Z, Chen SH, Li YM. Circulating MicroRNAs as potential biomarkers for alcoholic steatohepatitis. Liver Int 2013; 33: 1257-1265 [PMID: 23682678 DOI: 10.1111/liv.12196]
15. Jin X, Chen YP, Kong M, Zheng L, Yang YD, Li YM. Transition from hepatic steatosis to steatohepatitis: unique microRNA patterns and potential downstream functions and pathways. J Gastroenterol Hepatol 2012; 27: 331-340 [PMID: 21793903 DOI: 10.1111/j.1440-1746.2011.06864.x]
16. Jin X, Ye YF, Chen SH, Yu CH, Liu J, Li YM. MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease. Dig Liver Dis 2009; 41: 289-297 [PMID: 18922750 DOI: 10.1016/j.dld.2008.08.008]
17. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG. Clustal W and Clustal X version 2.0. Bioinformatics 2007; 23: 2947-2948 [PMID: 17846036 DOI: 10.1093/bioinformatics/btm404]
18. Baffy G. Uncoupling protein-2 and non-alcoholic fatty liver disease. Front Biosci 2005; 10: 2082-2096 [PMID: 15970480 DOI: 10.2741/1683]
19. Christian BE, Spremulli LL. Mechanism of protein biosynthesis in mammalian mitochondria. Biochim Biophys Acta 2012; 1819: 1035-1054 [PMID: 22172991]
20. Cowherd RB, Asmar MM, Alderman JM, Alderman EA, Garland AL, Busby WH, Bodnar WM, Rusyn I, Medoff BD, Tisch R, Mayer-Davis E, Swenberg JA, Zeisel SH, Combs TP. Adiponectin lowers glucose production by increasing SOGA. Am J Pathol 2010; 177: 1936-1945 [PMID: 20813965 DOI: 10.2353/ajpath.2010.100363]
21. Chaurasia SS, Gupta P, Maiti PK, Kar A. Possible involvement of lipid peroxidation in the inhibition of type I iodothyronine 5'-monodeiodinase activity by lead in chicken liver. J Appl Toxicol 2012; 18: 299-300 [PMID: 9719431]
22. Nomura F, Noda M, Miyake M, Nakai T. Long-term alcohol intake enhances ADP-ribosylation of the multifunctional enzyme, phosphoglucomutase, in rat liver. Hepatology 1996; 24: 1246-1249 [PMID: 8903405 DOI: 10.1002/hep.510240543]
23. Xu J, Kulkarni SR, Li L, Slitt AL. UDP-glucuronosyltransferase expression in mouse liver is increased in obesityand fasting-induced steatosis. Drug Metab Dispos 2012; 40: 259-266 [PMID: 22031624 DOI: 10.1124/dmd.111.039925]
24. Strickland KC, Krupenko NI, Dubard ME, Hu CJ, Tsybovsky Y, Krupenko SA. Enzymatic properties of ALDH1L2, a mitochondrial 10-formyltetrahydrofolate dehydrogenase. Chem Biol Interact 2011; 191: 129-136 [PMID: 21238436 DOI: 10.1016/j.cbi.2011.01.008]
25. Krupenko NI, Dubard ME, Strickland KC, Moxley KM, Oleinik NV, Krupenko SA. ALDH1L2 is the mitochondrial homolog of 10-formyltetrahydrofolate dehydrogenase. J Biol Chem 2010; 285: 23056-23063 [PMID: 20498374 DOI: 10.1074/ jbc.M110.128843]
26. Tsutsumi T, Matsuda M, Aizaki H, Moriya K, Miyoshi H, Fujie H, Shintani Y, Yotsuyanagi H, Miyamura T, Suzuki T, Koike K. Proteomics analysis of mitochondrial proteins reveals overexpression of a mitochondrial protein chaperon, prohibitin, in cells expressing hepatitis C virus core protein. Hepatology 2009; 50: 378-386 [PMID: 19591124 DOI: 10.1002/ hep.22998]
27. Tanno S, Fukuda I, Saito Y, Ogawa K. Prohibitin expression is decreased in the regenerating liver but not in chemically induced hepatic tumors in rats. Jpn J Cancer Res 1997; 88: 1155-1164 [PMID: 9473733 DOI: 10.1111/j.1349-7006.1997. tb00344.x]
28. Sánchez-Quiles V, Santamaría E, Segura V, Sesma L, Prieto J, Corrales FJ. Prohibitin deficiency blocks proliferation and induces apoptosis in human hepatoma cells: molecular mechanisms and functional implications. Proteomics 2010; 10: 1609-1620 [PMID: 20186755 DOI: 10.1002/pmic.200900757]
29. Crouser ED, Julian MW, Huff JE, Struck J, Cook CH. Carbamoyl phosphate synthase-1: a marker of mitochondrial damage and depletion in the liver during sepsis. Crit Care Med 2006; 34: 2439-2446 [PMID: 16791110 DOI: 10.1097/01. CCM.0000230240.02216.21]
30. Banasik K, Justesen JM, Hornbak M, Krarup NT, Gjesing AP, Sandholt CH, Jensen TS, Grarup N, Andersson A, Jørgensen T, Witte DR, Sandbæk A, Lauritzen T, Thorens B, Brunak S, Sørensen TI, Pedersen O, Hansen T. Bioinformatics- driven identification and examination of candidate genes for non-alcoholic fatty liver disease. PLoS One 2011; 6: e16542 [PMID: 21339799 DOI: 10.1371/journal.pone.0016542]
31. Jin X, Yang YD, Chen K, Lv ZY, Zheng L, Liu YP, Chen SH, Yu CH, Jiang XY, Zhang CY, Li YM. HDMCP uncouples yeast mitochondrial respiration and alleviates steatosis in L02 and hepG2 cells by decreasing ATP and H2O2 levels: a novel mechanism for NAFLD. J Hepatol 2009; 50: 1019-1028 [PMID: 19303656 DOI: 10.1016/j.jhep.2008.10.034]
32. Cioffi F, Senese R, de Lange P, Goglia F, Lanni A, Lombardi A. Uncoupling proteins: a complex journey to function discovery. Biofactors 2009; 35: 417-428 [PMID: 19626697 DOI: 10.1002/biof.54]
33. Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Takayanagi R, Nakamuta M. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 2007; 20: 351-358 [PMID: 17671740]